Abstract Library

#4576 Economic evidence for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

Introduction: Treatment failure and disease progression (PD) in neuroendocrine tumours (NETs), a rare group of malignancies, are common due to limited targeted treatments.

Conference:

Presenting Author:

Authors: Karim E, Sola-Morales O, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine Tumour, Systematic Literature Review, Economic,

#4494 Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,

#4095 CAPTEM and PRRT to improve overall response for pancreatic NETs (pNETs) – The CORONET trial

Introduction: Patients with advanced pNETs have limited treatment options. The NETTER-2 and OCLURANDOM trials have established peptide receptor radionuclide therapy (PRRT) as a standard treatment in pNETs; CAPTEM chemotherapy is an active regimen in NENs. The CONTROL NETs trial has shown promising response rate and progression-free survival with PRRT+CAPTEM, warranting further investigation.

Conference:

Presenting Author:

Authors: Chan D, Doherty M, Singh S, Michael M, Kong G,

Keywords: PRRT, CAPTEM, Randomized Trial, Phase III,

#4002 Efficacy and safety of Surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Preliminary results from a single-arm, phase II study

Introduction: Limited treatment options exist for advanced G2/G3 NETs. Many studies have shown improved efficacy with combined anti-angiogenic therapy and chemotherapy. However, no studies have reported on the use of surufatinib in combination with CAPTEM for NETs.

Conference:

Presenting Author:

Authors: Wang W, Liu Z, Yang X, Xue Z,

Keywords: g2/g3 nets, surufatinib, captem,

#3801 Local treatment of neuroendocrine liver metastases – How effective and safe is stereotactic microwave ablation?

Introduction: The less invasiveness of local ablation techniques such as stereotactic microwave ablation (SMWA) for the treatment of malignant hepatic lesions has made it an attractive alternative to conventional surgical resection.

Conference:

Presenting Author: Hanreich C

Authors: Hanreich C, Perrodin S, Candinas D, Lachenmayer A, Kim-Fuchs C,

Keywords: liver metastasis, microwave ablation, neuroendocrine tumor,